Dicot Pharma AB

OM:DICOT Stock Report

Market Cap: SEK 763.6m

Dicot Pharma Management

Management criteria checks 3/4

Dicot Pharma's CEO is Elin Trampe, appointed in Apr 2022, has a tenure of 3.08 years. total yearly compensation is SEK2.16M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth SEK248.92K. The average tenure of the management team and the board of directors is 2.8 years and 3.5 years respectively.

Key information

Elin Trampe

Chief executive officer

SEK 2.2m

Total compensation

CEO salary percentage100.00%
CEO tenure3.1yrs
CEO ownership0.03%
Management average tenure2.8yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Dicot Pharma (STO:DICOT) Is In A Good Position To Deliver On Growth Plans

Feb 26
Dicot Pharma (STO:DICOT) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Nov 12
Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09
We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23
We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Elin Trampe's remuneration changed compared to Dicot Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-SEK 67m

Dec 31 2024SEK 2mSEK 2m

-SEK 58m

Sep 30 2024n/an/a

-SEK 53m

Jun 30 2024n/an/a

-SEK 51m

Mar 31 2024n/an/a

-SEK 48m

Dec 31 2023SEK 2mSEK 2m

-SEK 44m

Sep 30 2023n/an/a

-SEK 37m

Jun 30 2023n/an/a

-SEK 34m

Mar 31 2023n/an/a

-SEK 32m

Dec 31 2022SEK 1mSEK 1m

-SEK 32m

Compensation vs Market: Elin's total compensation ($USD221.74K) is about average for companies of similar size in the Swedish market ($USD276.15K).

Compensation vs Earnings: Elin's compensation has increased whilst the company is unprofitable.

CEO

Elin Trampe (44 yo)

3.1yrs

Tenure

SEK 2,155,000

Compensation

Ms. Elin Trampe serves as Chief Executive Officer at Dicot Pharma AB (formerly known as Dicot AB (publ)) since April 1, 2022. She served as Vice President for Dicot Pharma AB (formerly known as Dicot AB (p...

Leadership Team

NamePositionTenureCompensationOwnership
Elin Trampe
Chief Executive Officer3.1yrsSEK 2.16m0.033%
SEK 248.9k
Jarl Wikberg
Founderno dataSEK 67.75kno data
Bjorn Petersson
Chief Financial Officer3.2yrsno datano data
Mats Silvander
Chief Technical Officer1.8yrsno datano data
Charlotta Gauffin
Chief Scientific Officer2.8yrsno data0.015%
SEK 115.2k
Hakan Wickholm
Chief Business Officerless than a yearno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Management: DICOT's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jan-Eric Österlund
Independent Director2yrsSEK 75.00kno data
Fredrik Buch
Independent Director3.1yrsSEK 75.00kno data
Michael Zell
Independent Director3.1yrsSEK 75.00k0.51%
SEK 3.9m
Per-Goran Gillberg
Independent Director4yrsSEK 125.00k0.030%
SEK 228.0k
Eva Saers
Independent Chairman of the Board4.5yrsSEK 170.00k0.041%
SEK 312.9k
Mikael von Euler
Independent Director7.3yrsSEK 75.00kno data

3.5yrs

Average Tenure

71yo

Average Age

Experienced Board: DICOT's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 05:41
End of Day Share Price 2025/05/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dicot Pharma AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.